<DOC>
	<DOCNO>NCT02913261</DOCNO>
	<brief_summary>To evaluate safety efficacy ruxolitinib compare Best Available Therapy patient corticosteroid-refractory acute graft vs. host disease allogeneic stem cell transplantation</brief_summary>
	<brief_title>Safety Efficacy Ruxolitinib Versus Best Available Therapy Patients With Corticosteroid-refractory Acute Graft v . Host Disease After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Have undergone Allogeneic Stem Cell Transplanttaion ( alloSCT ) donor source ( match unrelated donor , sibling , haploidentical ) use bone marrow , peripheral blood stem cell , cord blood . Recipients non myeloablative , myeloablative , reduced intensity conditioning eligible Clinically diagnose Grades II IV acute GvHD per standard criterion occur alloSCT require systemic immune suppressive therapy . Biopsy involved organ aGvHD encourage require study screen . Confirmed diagnosis steroid refractory aGvHD ( confirm within 48h prior study treatment start ) define patient administer highdose systemic corticosteroid ( methylprednisolone 2 mg/kg/day [ equivalent prednisone dose 2.5 mg/kg/day ] ) , give alone combine calcineurin inhibitor ( CNI ) either : Progressing base organ assessment 5 day compare organ stage time initiation highdose systemic corticosteroid +/ CNI treatment Grade IIIV aGvHD , OR Failure achieve minimum partial response base organ assessment 7 day compare organ stage time initiation highdose systemic corticosteroid +/ CNI treatment Grade IIIV aGvHD , OR Patients fail corticosteroid taper define fulfil either one follow criterion : Requirement increase corticosteroid dose methylprednisolone ≥2 mg/kg/day ( equivalent prednisone dose ≥2.5 mg/kg/day ) , OR Failure taper methylprednisolone dose &lt; 1 mg/kg/day ( equivalent prednisone dose &lt; 1.25 mg/kg/day ) minimum 7 day . Has receive one systemic treatment aGvHD , corticosteroid +/ CNI ( prophylaxis treatment ) . Presence active uncontrolled infection include significant bacterial , fungal , viral parasitic infection require treatment . Infections consider controlled appropriate therapy institute , time screening , sign progression present . Progression infection define hemodynamic instability attributable sepsis , new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Evidence active viral infection ( confirmed peripheral blood viral load ) include Cytomegalovirus ( CMV ) , EpsteinBarr Virus ( EBV ) , Human Herpes Virus6 ( HHV6 ) , Hepatitis Virus ( HBV ) , Hepatitis C Virus ( HCV ) . Patients pretransplant positive serology result indicative high risk viral reactivation must negative viral load result within 28 day prior randomization . Patients whose immune status unknown uncertain ( e.g . serology obtain prior transplant ) must viral load result confirm evidence active viral infection within 28 day prior randomization . Presence relapse primary malignancy , treat relapse alloHSCT perform , may require rapid immune suppression withdrawal preemergent treatment early malignancy relapse . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GvHD ( Graft versus Host Disease )</keyword>
	<keyword>INC424</keyword>
	<keyword>ruxolitinib</keyword>
	<keyword>best available therapy ( BAT )</keyword>
	<keyword>corticosteroid-refractory acute graft vs. host disease</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>steroid refractory acute graft vs. host disease</keyword>
	<keyword>Janus Kinase ( JAK ) inhibitor</keyword>
</DOC>